Pub Date : 2024-10-01DOI: 10.1016/j.ekir.2024.08.023
Michel Y. Jadoul , Laura Labriola
{"title":"Fracture Risk in Patients on Hemodialysis: the Lower the Parathyroid Hormone the Better?","authors":"Michel Y. Jadoul , Laura Labriola","doi":"10.1016/j.ekir.2024.08.023","DOIUrl":"10.1016/j.ekir.2024.08.023","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142223890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-01DOI: 10.1016/j.ekir.2024.08.001
Jessica K. Kaufeld , Lucas Kühne , Ulf Schönermarck , Jan Hinrich Bräsen , Constantin von Kaisenberg , Bodo B. Beck , Florian Erger , Carsten Bergmann , Anke von Bergwelt-Baildon , Paul T. Brinkkötter , Linus A. Völker , Jan Menne
{"title":"Erratum to “Features of Postpartum Hemorrhage-Associated Thrombotic Microangiopathy and Role of Short-Term Complement Inhibition” [Kidney International Reports Volume 9, Issue 4, April 2024, Pages 919-928]","authors":"Jessica K. Kaufeld , Lucas Kühne , Ulf Schönermarck , Jan Hinrich Bräsen , Constantin von Kaisenberg , Bodo B. Beck , Florian Erger , Carsten Bergmann , Anke von Bergwelt-Baildon , Paul T. Brinkkötter , Linus A. Völker , Jan Menne","doi":"10.1016/j.ekir.2024.08.001","DOIUrl":"10.1016/j.ekir.2024.08.001","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141941210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-01DOI: 10.1016/j.ekir.2024.07.038
Thomas A. Mavrakanas , Amélie Marsot , Efrosyne Tsirella , Norka Rios , Ari Gritsas , Rita S. Suri
{"title":"Canagliflozin Pharmacokinetics at Steady State in Patients on Maintenance Hemodialysis","authors":"Thomas A. Mavrakanas , Amélie Marsot , Efrosyne Tsirella , Norka Rios , Ari Gritsas , Rita S. Suri","doi":"10.1016/j.ekir.2024.07.038","DOIUrl":"10.1016/j.ekir.2024.07.038","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142181696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-01DOI: 10.1016/j.ekir.2024.07.033
Jihyun Yang , Kyu-Beck Lee , Hyang Kim , Soo Wan Kim , Yeong Hoon Kim , Su Ah Sung , Jayoun Kim , Kook-Hwan Oh , Ji Yong Jung , Young Youl Hyun
Introduction
Statin treatment can reduce the risk of cardiovascular disease (CVD). Paradoxically, previous studies have shown that the use of statin is associated with the progression coronary artery calcification (CAC), a well-known predictor of CVD, in individuals with preserved renal function or in patients on dialysis. However, little is known about the association in patients with predialysis chronic kidney disease (CKD). The aim of this study was to characterize the relationship between statin use and progression of CAC in a CKD cohort of Korean adults.
Methods
We analyzed 1177 participants registered in the Korean Cohort Study for Outcome in Patients with Chronic Kidney Disease (KNOW-CKD) cohort. Coronary artery calcium score (CACS) was assessed using cardiac computed tomography at baseline and 4 years after enrollment. CAC progression was defined using the Sevrukov method. Statin users were defined as those who used statins for 50% or more of the follow-up period.
Results
The median (interquartile range) of CACS was 0 (0–30.33), and 318 (44.2%) participants had CACS above 0 at baseline. There were 447 (38.0%) statin users and 730 (62.0%) statin nonusers. After 4 years, 374 patients (52.0%) demonstrated CAC progression, which was significantly more frequent in statin users than in statin nonusers (218 [58.3%] vs. 156 [41.7%], P < 0.001). The multivariate-adjusted odds ratio for CAC progression in statin users compared to statin nonusers was 1.78 (1.26–2.50).
Conclusion
Statin use, significantly and independently, is associated with CAC progression in Korean patients with predialysis CKD. Further research is warranted to verify the prognosis of statin-related CAC progression.
{"title":"Statin Use and the Progression of Coronary Artery Calcification in CKD: Findings From the KNOW-CKD Study","authors":"Jihyun Yang , Kyu-Beck Lee , Hyang Kim , Soo Wan Kim , Yeong Hoon Kim , Su Ah Sung , Jayoun Kim , Kook-Hwan Oh , Ji Yong Jung , Young Youl Hyun","doi":"10.1016/j.ekir.2024.07.033","DOIUrl":"10.1016/j.ekir.2024.07.033","url":null,"abstract":"<div><h3>Introduction</h3><div>Statin treatment can reduce the risk of cardiovascular disease (CVD). Paradoxically, previous studies have shown that the use of statin is associated with the progression coronary artery calcification (CAC), a well-known predictor of CVD, in individuals with preserved renal function or in patients on dialysis. However, little is known about the association in patients with predialysis chronic kidney disease (CKD). The aim of this study was to characterize the relationship between statin use and progression of CAC in a CKD cohort of Korean adults.</div></div><div><h3>Methods</h3><div>We analyzed 1177 participants registered in the Korean Cohort Study for Outcome in Patients with Chronic Kidney Disease (KNOW-CKD) cohort. Coronary artery calcium score (CACS) was assessed using cardiac computed tomography at baseline and 4 years after enrollment. CAC progression was defined using the Sevrukov method. Statin users were defined as those who used statins for 50% or more of the follow-up period.</div></div><div><h3>Results</h3><div>The median (interquartile range) of CACS was 0 (0–30.33), and 318 (44.2%) participants had CACS above 0 at baseline. There were 447 (38.0%) statin users and 730 (62.0%) statin nonusers. After 4 years, 374 patients (52.0%) demonstrated CAC progression, which was significantly more frequent in statin users than in statin nonusers (218 [58.3%] vs. 156 [41.7%], <em>P</em> < 0.001). The multivariate-adjusted odds ratio for CAC progression in statin users compared to statin nonusers was 1.78 (1.26–2.50).</div></div><div><h3>Conclusion</h3><div>Statin use, significantly and independently, is associated with CAC progression in Korean patients with predialysis CKD. Further research is warranted to verify the prognosis of statin-related CAC progression.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142181699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-01DOI: 10.1016/j.ekir.2024.07.029
Juergen Grafeneder , Wisse van Os , Iris K. Minichmayr , Katarina D. Kovacevic Miljevic , Birgit Reiter , Marcus D. Säemann , Veronika Machold-Fabrizii , Amro Ahmed , Paul Spechtl , Haris Omic , Raute Sunder-Plaßmann , Bernd Jilma , Christian Schoergenhofer , Farsad Eskandary
Introduction
Hemodialysis patients (HDPs) exhibit extensive cardiovascular risk. The widely prescribed anti-platelet agent clopidogrel is metabolically activated by cytochrome enzymes, which may be impaired by uremia and chronic low-grade inflammation, typically present in HDPs. We conducted a prospective multicenter study to investigate the pharmacokinetics and pharmacodynamics of clopidogrel in HDPs and healthy volunteers (HVs).
Methods
We enrolled HDPs receiving long-term clopidogrel (75 mg) and pantoprazole treatment (40 mg). Healthy volunteers received a loading dose of 300 mg clopidogrel, followed by 75 mg once daily. Pantoprazole, a substrate and probe drug of CYP2C19, was administered intravenously (40 mg). Plasma concentrations were quantified by mass spectrometry. Pharmacokinetics were calculated, and a population pharmacokinetic model was developed. The primary endpoint was the maximum concentration of clopidogrel’s active metabolite. Platelet aggregation was measured using adenosine diphosphate-induced whole-blood aggregometry.
Results
Seventeen HDPs and 16 HVs were included. The maximum concentration of clopidogrel’s active metabolite was significantly lower in HDPs compared to HVs (median [interquartile range] 12.2 [4.6–23.4] vs. 24.7 [17.8–36.5] ng/ml, P = 0.02). The maximum concentration ratio of clopidogrel’s active metabolite to prodrug was 8.5-fold lower in HDPs, and an 82.7% reduced clopidogrel clearance, including clopidogrel’s active metabolite formation, was found using population pharmacokinetic modeling. From previous studies, adenosine diphosphate-induced platelet aggregation at 120 minutes was significantly higher in HDPs than in HVs (median [interquartile range]: 26 U [14 U–43 U] vs. 12 U [11 U–18 U], P = 0.004. Pantoprazole terminal half-life was ∼1.7-fold higher in HDPs compared to HVs.
Conclusion
Our data demonstrate an altered metabolism of clopidogrel in HDPs in the context of lower CYP2C19 activity, with potential implications for other substances metabolized by this enzyme.
{"title":"Prospective Trial on the Pharmacokinetics of Clopidogrel in Hemodialysis Patients","authors":"Juergen Grafeneder , Wisse van Os , Iris K. Minichmayr , Katarina D. Kovacevic Miljevic , Birgit Reiter , Marcus D. Säemann , Veronika Machold-Fabrizii , Amro Ahmed , Paul Spechtl , Haris Omic , Raute Sunder-Plaßmann , Bernd Jilma , Christian Schoergenhofer , Farsad Eskandary","doi":"10.1016/j.ekir.2024.07.029","DOIUrl":"10.1016/j.ekir.2024.07.029","url":null,"abstract":"<div><h3>Introduction</h3><div>Hemodialysis patients (HDPs) exhibit extensive cardiovascular risk. The widely prescribed anti-platelet agent clopidogrel is metabolically activated by cytochrome enzymes, which may be impaired by uremia and chronic low-grade inflammation, typically present in HDPs. We conducted a prospective multicenter study to investigate the pharmacokinetics and pharmacodynamics of clopidogrel in HDPs and healthy volunteers (HVs).</div></div><div><h3>Methods</h3><div>We enrolled HDPs receiving long-term clopidogrel (75 mg) and pantoprazole treatment (40 mg). Healthy volunteers received a loading dose of 300 mg clopidogrel, followed by 75 mg once daily. Pantoprazole, a substrate and probe drug of <em>CYP2C19</em>, was administered intravenously (40 mg). Plasma concentrations were quantified by mass spectrometry. Pharmacokinetics were calculated, and a population pharmacokinetic model was developed. The primary endpoint was the maximum concentration of clopidogrel’s active metabolite. Platelet aggregation was measured using adenosine diphosphate-induced whole-blood aggregometry.</div></div><div><h3>Results</h3><div>Seventeen HDPs and 16 HVs were included. The maximum concentration of clopidogrel’s active metabolite was significantly lower in HDPs compared to HVs (median [interquartile range] 12.2 [4.6–23.4] vs. 24.7 [17.8–36.5] ng/ml, <em>P =</em> 0.02). The maximum concentration ratio of clopidogrel’s active metabolite to prodrug was 8.5-fold lower in HDPs, and an 82.7% reduced clopidogrel clearance, including clopidogrel’s active metabolite formation, was found using population pharmacokinetic modeling. From previous studies, adenosine diphosphate-induced platelet aggregation at 120 minutes was significantly higher in HDPs than in HVs (median [interquartile range]: 26 U [14 U–43 U] vs. 12 U [11 U–18 U], <em>P =</em> 0.004. Pantoprazole terminal half-life was ∼1.7-fold higher in HDPs compared to HVs.</div></div><div><h3>Conclusion</h3><div>Our data demonstrate an altered metabolism of clopidogrel in HDPs in the context of lower <em>CYP2C19</em> activity, with potential implications for other substances metabolized by this enzyme.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142181706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-01DOI: 10.1016/j.ekir.2024.07.027
Zhuo-ran Song , Yang Li , Hong Zhang , Xu-jie Zhou
{"title":"A Pilot Study on Protective Effect of Ambrisentan on Proteinuria in Patients With Alport Syndrome","authors":"Zhuo-ran Song , Yang Li , Hong Zhang , Xu-jie Zhou","doi":"10.1016/j.ekir.2024.07.027","DOIUrl":"10.1016/j.ekir.2024.07.027","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142181738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-01DOI: 10.1016/j.ekir.2024.07.018
Daniil Shimonov , Sri Lekha Tummalapalli , Stephanie Donahue , Vidya Narayana , Sylvia Wu , Lisa S. Walters , Roberta Billman , Barbara Desiderio , Sandra Pressman , Oliver Fielding , Kariel Sweeney , Daniel Cukor , Daniel M. Levine , Thomas S. Parker , Vesh Srivatana , Jeffrey Silberzweig , Frank Liu , Andrew Bohmart
Introduction
Multidisciplinary care (MDC) for late-stage chronic kidney disease (CKD) has been associated with improved patient outcomes compared with traditional nephrology care; however, the optimal MDC model is unknown. In 2015, we implemented a novel MDC model for patients with late-stage CKD informed by the Chronic Care Model conceptual framework, including an expanded MDC team, care plan meetings, clinical risk prediction, and a patient dashboard.
Methods
We conducted a single-center, retrospective cohort study of adults with late-stage CKD (estimated glomerular filtration rate [eGFR] < 30 ml/min per 1.73 m2) enrolled from May 2015 to February 2020 in the Program for Education in Advanced Kidney Disease (PEAK). Our primary composite outcome was an optimal transition to end-stage kidney disease (ESKD) defined as starting in-center hemodialysis (ICHD) as an outpatient with an arteriovenous fistula (AVF) or graft (AVG), or receiving home dialysis, or a preemptive kidney transplant. Secondary outcomes included home dialysis initiation, preemptive transplantation, vascular access at dialysis initiation, and location of ICHD initiation. We used logistic regression to examine trends in outcomes. Results were stratified by race, ethnicity, and insurance payor, and compared with national and regional averages from the United States Renal Data System (USRDS) averaged from 2015 to 2019.
Results
Among 489 patients in the PEAK program, 37 (8%) died prior to ESKD and 151 (31%) never progressed to ESKD. Of the 301 patients (62%) who progressed to ESKD, 175 (58%) achieved an optimal transition to ESKD, including 54 (18%) on peritoneal dialysis, 16 (5%) on home hemodialysis, and 36 (12%) to preemptive transplant. Of the 195 patients (65%) starting ICHD, 51% started with an AVF or AVG and 52% started as an outpatient. The likelihood of starting home dialysis increased by 1.34 times per year from 2015 to 2020 (95% confidence interval [CI]: 1.05–1.71, P = 0.018) in multivariable adjusted results. Optimal transitions to ESKD and home dialysis rates were higher than the national USRDS data (58% vs. 30%; 23% vs. 11%) across patient race, ethnicity, and payor.
Conclusion
Patients enrolled in a novel comprehensive MDC model coupled with risk prediction and health information technology were nearly twice as likely to achieve an optimal transition to ESKD and start dialysis at home, compared with national averages.
{"title":"Clinical Outcomes of a Novel Multidisciplinary Care Program in Advanced Kidney Disease (PEAK)","authors":"Daniil Shimonov , Sri Lekha Tummalapalli , Stephanie Donahue , Vidya Narayana , Sylvia Wu , Lisa S. Walters , Roberta Billman , Barbara Desiderio , Sandra Pressman , Oliver Fielding , Kariel Sweeney , Daniel Cukor , Daniel M. Levine , Thomas S. Parker , Vesh Srivatana , Jeffrey Silberzweig , Frank Liu , Andrew Bohmart","doi":"10.1016/j.ekir.2024.07.018","DOIUrl":"10.1016/j.ekir.2024.07.018","url":null,"abstract":"<div><h3>Introduction</h3><div>Multidisciplinary care (MDC) for late-stage chronic kidney disease (CKD) has been associated with improved patient outcomes compared with traditional nephrology care; however, the optimal MDC model is unknown. In 2015, we implemented a novel MDC model for patients with late-stage CKD informed by the Chronic Care Model conceptual framework, including an expanded MDC team, care plan meetings, clinical risk prediction, and a patient dashboard.</div></div><div><h3>Methods</h3><div>We conducted a single-center, retrospective cohort study of adults with late-stage CKD (estimated glomerular filtration rate [eGFR] < 30 ml/min per 1.73 m<sup>2</sup>) enrolled from May 2015 to February 2020 in the Program for Education in Advanced Kidney Disease (PEAK). Our primary composite outcome was an optimal transition to end-stage kidney disease (ESKD) defined as starting in-center hemodialysis (ICHD) as an outpatient with an arteriovenous fistula (AVF) or graft (AVG), or receiving home dialysis, or a preemptive kidney transplant. Secondary outcomes included home dialysis initiation, preemptive transplantation, vascular access at dialysis initiation, and location of ICHD initiation. We used logistic regression to examine trends in outcomes. Results were stratified by race, ethnicity, and insurance payor, and compared with national and regional averages from the United States Renal Data System (USRDS) averaged from 2015 to 2019.</div></div><div><h3>Results</h3><div>Among 489 patients in the PEAK program, 37 (8%) died prior to ESKD and 151 (31%) never progressed to ESKD. Of the 301 patients (62%) who progressed to ESKD, 175 (58%) achieved an optimal transition to ESKD, including 54 (18%) on peritoneal dialysis, 16 (5%) on home hemodialysis, and 36 (12%) to preemptive transplant. Of the 195 patients (65%) starting ICHD, 51% started with an AVF or AVG and 52% started as an outpatient. The likelihood of starting home dialysis increased by 1.34 times per year from 2015 to 2020 (95% confidence interval [CI]: 1.05–1.71, <em>P</em> = 0.018) in multivariable adjusted results. Optimal transitions to ESKD and home dialysis rates were higher than the national USRDS data (58% vs. 30%; 23% vs. 11%) across patient race, ethnicity, and payor.</div></div><div><h3>Conclusion</h3><div>Patients enrolled in a novel comprehensive MDC model coupled with risk prediction and health information technology were nearly twice as likely to achieve an optimal transition to ESKD and start dialysis at home, compared with national averages.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141851688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Climate Change, Heat Stress, and Kidney Disease–Associated Mortality and Health Care Utilization","authors":"Naresh Kumar , Venkata Madhavi Latha Telagarapu , Alessia Fornoni","doi":"10.1016/j.ekir.2024.08.018","DOIUrl":"10.1016/j.ekir.2024.08.018","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142181669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-01DOI: 10.1016/j.ekir.2024.08.011
Guisen Li , Susan J. Thanabalasingam
{"title":"Urinary Soluble CD163: A Novel Biomarker Suggests Who Should Receive Glucocorticoids in IgA Nephropathy","authors":"Guisen Li , Susan J. Thanabalasingam","doi":"10.1016/j.ekir.2024.08.011","DOIUrl":"10.1016/j.ekir.2024.08.011","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142181695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-01DOI: 10.1016/j.ekir.2024.07.010
Madan M. Bahadur , Nikhil Dhope , Rejitha R. Kaimal , Ashay Shingare
{"title":"Pilot Study of Valganciclovir-Induced Leukopenia in Kidney Transplant Recipients With NUDT15 Genetic Variation","authors":"Madan M. Bahadur , Nikhil Dhope , Rejitha R. Kaimal , Ashay Shingare","doi":"10.1016/j.ekir.2024.07.010","DOIUrl":"10.1016/j.ekir.2024.07.010","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":null,"pages":null},"PeriodicalIF":5.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141839194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号